Natera, Inc. announced the launch of the TEODOR trial (ABCSG 61), a Phase II, multicenter, randomized controlled trial. This study aims to optimize systemic therapy in early-stage breast cancer by potentially replacing chemotherapy with endocrine therapy for a subset of patients.
The TEODOR trial is designed for women with hormone receptor-positive (HR+), HER2-negative breast cancer who are endocrine responsive and test negative with Signatera. The study expects to enroll approximately 250 patients across 15 sites in Austria.
The primary endpoint of the study is the rate of neoadjuvant therapy response, assessed via pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score. This trial represents a critical step toward more personalized medicine, leveraging Signatera to guide treatment de-escalation and potentially reduce chemotherapy side effects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.